Genetic Testing for ATTR-CM

Genetic Testing and ATTR-CM: Everything You Need to Know

Genetic Testing and ATTR-CM: Everything You Need to Know
Csaba Deli/Adobe Stock

Genetic testing is an important part of the diagnosis process for transthyretin cardiac amyloidosis (ATTR-CM). It’s not only key to managing your care but also helps you determine whether others in your family have the condition or are at risk.

ATTR-CM occurs when an irregular protein called transthyretin, or TTR, is produced in the liver and builds up in the heart. This buildup stiffens the walls of the heart, making it harder for the heart to pump blood. Eventually, it can lead to heart failure.

Genetic testing can help reduce your risk of such complications, as well as protect your loved ones.

Why Everyone With ATTR-CM Should Be Tested

If you have ATTR-CM, you may be aware that there are two types of the condition:

  • Hereditary ATTR-CM runs in families and can cause symptoms around age 30 or later. It leads to amyloid deposits in the heart, nerves, kidneys, and other organs.
  • Wild-type ATTR-CM doesn’t run in families and tends to occur in older men. It mostly affects the heart, but it may also cause problems like carpal tunnel syndrome or pain or numbness in the hands or feet.
After a person is diagnosed with ATTR-CM, genetic testing is the next step, says Trejeeve Martyn, MD, a cardiologist in Cleveland Clinic’s heart failure and cardiac transplantation section in Ohio. Results can tell you and your care team which type of ATTR-CM you have, so you can treat it as effectively as possible.

Why Hereditary ATTR-CM Is Different

There isn’t a cure for ATTR-CM, nor are there treatments to reverse existing amyloid buildup. However, disease-modifying therapies do make it possible to slow the buildup of new amyloid deposits, improving both life expectancy and quality of life in people with hereditary ATTR-CM.

These therapies deliver the biggest benefit when they’re started early, before ATTR-CM becomes severe.

“ATTR-CM is a progressive disorder,” says Dr. Martyn. “The earlier the disease is diagnosed, the better the prognosis, response to therapy, and quality of life patients tend to have.”

Disease-modifying therapies include:

  • Stabilizer Agents Oral medications like acoramidis (Attruby) and tafamidis (Vyndamax) make it harder for TTR proteins to misfold and create amyloid deposits.
  • TTR Silencers Injectable medication vutrisiran (Amvuttra) limits how much TTR the body produces, thereby limiting the production of amyloid deposits.
Your cardiologist may also prescribe additional medications to help manage symptoms caused by ATTR-CM, such as swelling, shortness of breath, heart palpitations, and high blood pressure, or to reduce your risk for complications like blood clots.

Hereditary ATTR-CM and Family Risk

Hereditary ATTR-CM is an inherited condition that can be passed down from parents to children. The American Heart Association (AHA) estimates that a person with a parent or sibling with hereditary ATTR-CM has a 50 percent chance of carrying a genetic variant tied to the condition.

Approximately 130 different genetic variants are linked to hereditary ATTR-CM.

V122l is one of the most common, and it’s frequently found in people of African descent, occurring in up to 4 percent of African Americans.

If you have a genetic variant of hereditary ATTR-CM but don’t have any signs of the actual condition, you’re considered to be asymptomatic and may develop symptoms later in life. “This person should be followed by their healthcare team with surveillance testing to ensure no symptoms or signs arise in the future,” says James Ampadu, MD, a cardiologist specializing in heart failure with Prisma Health in Columbia, South Carolina.

Does Your Family Need Genetic Testing?

When a person is diagnosed with hereditary ATTR-CM, the AHA recommends that all of their first-degree relatives — father, mother, siblings, and children — consider genetic testing.

There aren’t official recommendations for how soon testing should happen, but sooner is generally better. Treatments for ATTR-CM are more effective when they’re started early, before the condition becomes severe.

Early diagnosis and treatment also helps people with ATTR-CM live longer.

Genetic Counseling: What You Should Know

The genetic testing process is quick and easy: You simply give a blood, saliva, or cheek swab sample, which is then sent off to a laboratory for analysis. Results are ready within a few weeks.

Genetic testing is typically covered by insurance, and free testing may be available for those who don’t have coverage or health insurance.

But the decision to undergo genetic testing can sometimes be stressful. “Genetic testing has implications for the future and can affect family members,” says Quan M. Bui, MD, a cardiologist at UC San Diego Health and assistant professor of medicine at the University of California San Diego School of Medicine.

That’s where genetic counseling comes in. These healthcare professionals have special training in medical genetics, and they can walk you through how hereditary ATTR-CM may affect you or a family member. They can also help you interpret your test results and determine your next steps for care or continued monitoring.

The Takeaway

  • Genetic testing is essential for determining whether a person has the hereditary form of ATTR-CM, which runs in families, or wild type ATTR-CM, which does not, allowing doctors to tailor treatment plans effectively.
  • Because ATTR-CM is a progressive disorder with no known cure, early diagnosis with genetic testing allows for the timely use of disease-modifying therapies that help slow protein buildup and improve life expectancy.
  • Since first-degree relatives of those with hereditary ATTR-CM have a 50 percent chance of carrying a genetic variant linked to the condition, medical experts recommend that family members undergo testing to identify their risk before severe symptoms develop.
  • The testing process is a simple blood or saliva sample that’s often covered by insurance; however, because results can be emotionally difficult to navigate, genetic counselors are available to help families interpret data and plan for long-term monitoring.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Transthyretin Amyloidosis (ATTR). Cleveland Clinic. March 2, 2026.
  2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). American Heart Association. May 29, 2024.
  3. Bui QM et al. Patient Perspectives on Genetic Testing in Transthyretin Amyloid Cardiomyopathy: Framing the Conversation to Improve Implementation. Journal of Cardiac Failure – Intersections. September 1, 2025.
  4. Genetic Testing and Counseling for Hereditary Transthyretin Amyloidosis (hATTR). American Heart Association. May 31, 2024.
  5. Margolin E et al. Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy. Cardiology and Therapy. July 19, 2025.
  6. Jain A et al. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). StatPearls. April 27, 2023.
  7. Merino-Merino A et al. Utility of Genetic Testing in Patients With Transthyretin Amyloid Cardiomyopathy: A Brief Review. Biomedicines. December 21, 2023.
  8. Hereditary ATTR Amyloidosis. Amyloidosis Research Consortium.
  9. Kittleson MM et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. July 1, 2020.
  10. Ioannou A et al. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. Circulation. November 3, 2022.
joy-tanaka-bio

Joy Tanaka, PhD

Medical Reviewer

Joy Tanaka, PhD, specializes in clinical molecular genetics. She is dedicated to integrating excellent clinical care with cutting-edge medical research for patients with rare and u...

Marygrace Taylor

Marygrace Taylor

Author

Marygrace Taylor is an award-winning freelance health and wellness writer with more than 15 years of experience covering topics including women’s health, nutrition, chronic conditi...